|
|
News
11 Feb 2008: Medical Solutions enters an exclusive UK agreement with Empire Genomics, LLC as a distributor and service provider for ACCUArray genotyping
Medical Solutions enters an exclusive UK agreement with Empire Genomics, LLC as a distributor and service provider for ACCUArray genotyping
The Board of Medical Solutions plc (LSE: MLS), the provider of expert, quality DNA sequencing and genotyping services to the healthcare, pharma biotech and life sciences research sectors, is pleased to announce that it will partner with Empire Genomics, Inc. to be the exclusive UK distributor and service provider for its ACCUArray array comparative genomic hybridization (“aCGH”) genotyping technology.
In addition to distributing the product, Medical Solutions will also offer the genotyping service from its laboratories in Nottingham, which will include in-house bioinformatics analysis and support.
HIGHLIGHTS
- Exclusive distributor and service provider in the UK;
- Medical Solutions to offer both Human and Mouse ACCUArray aCGH as a product and also provide the genotyping service that will include in-house bioinformatic analysis;
- Novel DNA array for pre-natal, cancer and pharmacogenetic testing with diagnostic and research applications;
- Enhanced portfolio of genomic products and services provided in GLP, GCP and CPA accredited laboratories.
The addition of Empire Genomics ACCUArray will complement Medical Solutions existing portfolio of genomic products and contract research services including DNA clones and genomic analyses. The assay has clinical diagnostic applications for the healthcare community and can be used for pharmacogenetic testing by companies in the pharma biotech sector. This further demonstrates the Company’s commitment to be a market leader in the UK for the provision of expert, quality laboratory services and genomic reagents to the healthcare and life science research sectors.
Dr Tom Weaver, Commercial Director for Medical Solutions, said “The diagnostic capability of this assay is of particular interest to those groups in the healthcare community involved in cytogenetic and pre and post natal testing. ACCUArray aCGH provides a tremendous tool for the identification of genetic aberrations linked with a number of diseases and conditions such as cancer, autism, mental health problems including Alzheimer’s, several congenital abnormalities and certain syndromes including Down Syndrome”.
Dr Weaver added “The Empire Genomics aCGH kit, provides a high resolution and robust screening procedure for researchers, clinicians and pharmacologists. The supporting software provides data analysis within 24 hours in a concise and accessible format.”
Contact:
Dr. Andy Walker
Commercial Development Manager
Tel: 01223 432 607
andy.walker@medical-solutions.co.uk
04 Feb 2008: First UK commercial service provider of Illumina next generation DNA sequencing and genotyping applications
Medical Solutions becomes first UK commercial service provider of Illumina next generation DNA sequencing and genotyping applications
The Board of Medical Solutions plc (LSE: MLS), a UK-based provider of expert, quality DNA sequencing and genotyping services to the healthcare, pharma biotech and life sciences research sectors, is pleased to announce that it is implementing a new technology platform at its Nottingham laboratory that will help to broaden the Company’s offering and increase efficiencies.
Medical Solutions will become the UK’s first commercial service provider for these leading edge systems, which it will be sourcing fromIllumina, Inc.
HIGHLIGHTS
-
Complete pipeline of histopathology to genomic services, including DNA extraction, biobanking, whole genome amplification and DNA sequencing in GLP, GCP and CPA accredited laboratories
Adoption of Illumina’s DNA sequencing and genotyping platforms will complement Medical Solutions’ extensive portfolio of diagnostic and contract research services ranging from cell and tissue to genomic analysis. This further demonstrates the Company’s commitment to be a market leader in the UK for the provision of expert, quality laboratory services to the healthcare, pharma biotech and life science research sectors.
Dr Tom Weaver, Commercial Director for Medical Solutions said, "We selected the Illumina platforms because the data quality, reproducibility, flexibility and breadth of applications are, in our opinion, the best in the industry. This represents cutting edge technology capable of revealing an enormous volume of genetic information. Customers have already expressed significant interest in applications run on the Genome Analyzer and BeadStation platforms, and it is our intention to develop strategic partnerships with these early adopters, enabling them to take full advantage of the power of whole genome analysis by providing high-quality data in an accredited quality laboratory environment. "
Dr. Weaver added, “Illumina DNA sequencing and genotyping platforms are also capable of delivering analyses in the expanding field of personalised genomic services.”
“The addition of Illumina’s Genome Analyzer and BeadStation platforms demonstrates the level of commitment Medical Solutions has to its customers and to providing them with leading-edge technologies that enable whole genome analysis” said Karen Possemato, Director of Corporate Marketing at Illumina. “Their added interest in becoming an Illumina CSPro further supports the value Medical Solutions sees in Illumina’s products and how this program can be a key factor in their success.”
Contact:
Dr. Cheng Eng Ang
Commercial Manager
Tel: 01223 432 608
Mob: 07919 341 172
cheng-eng.ang@medical-solutions.co.uk
08 Jan 2008: Invitation to attend Medical Solutions Nottingham laboratory open day on 22nd January 2008
Medical Solutions plc
Invitation to attend contract research services laboratory open day
Nottingham
22 January 2008
Tour of state of the art laboratories at 11.00am and 4.00pm
Lunch & refreshments available
Medical Solutions, a leading provider of expert, quality services and products to the Healthcare, Pharma Biotech and Life Science Research sectors, will be holding an Open Day at its newly commissioned contract research services laboratory in Nottingham on 22 January 2008. There will also be an opportunity to view our state of the art reference laboratory facilities.
This Open Day provides an ideal opportunity to inform our customers, academic and research institutions of the full range of services and expertise offered by the Company and we very much hope it is an invitation you will be interested in accepting.
It is planned to have two tours of the laboratories, at 11am and 4pm, at which key laboratory managers and staff will be on hand to answer any questions you may have. Each tour will be preceded by a short presentation delivered by senior management, covering key activities including:
-
DNA sequencing, genotyping and gene expression analysis
-
Molecular pathology including FISH, HPV, KRAS, OncotypeDX™ and other diagnostic assays
-
Automated imaging and digital image capture and analysis
-
Biobanking (DNA and tissue) and clinical trials
-
Histopathology and cytology
-
Immunohistochemistry and antibody cross reactivity
Refreshments will be available after both lab tours, providing a further opportunity to network with senior management and technical personnel.
May I ask that you respond to this email by Thursday 17th January, indicating whether or not you will be attending and which session would be your preference (morning or afternoon). The following link gives directions to our location at Nottingham Business Park http://www.medical-solutions.co.uk/directions.aspx, where there is ample car parking.
To book your place on a tour, or for further details, please contact Stephanie McHugh on 01223 432 620 or Stephanie.mchugh@medical-solutions.co.uk. We very much hope that we will have the pleasure of welcoming you to Medical Solutions on the 22nd January.
Kind regards
Stephanie McHugh
Marketing Specialist
Tel: 01223 432620
Medical Solutions plc
1, Orchard Place
Nottingham Business Park
Nottingham
NG8 6PX
22 Nov 2007: Medical Solutions Geneservice Mini Exhibitions - New Dates Added
Medical Solutions Geneservice, provider of genomic products and contract research services, will be holding a series of mini exhibitions designed to inform the research community how the Company can help in the areas of:
• DNA Sequencing (free trials available)
• Gene expression analysis
• Genotyping
• Whole Genome Amplification
• cDNA/genomic/miRNA clones and libraries
Planned dates and venues:
v Friday 23rd November
10am – 2pm
School of Biosciences, University of Birmingham
v Tuesday 27th November
10am – 2pm
School of Biosciences, University of Nottingham
v Thursday 29th November
10am – 2pm
School of Biomedical Sciences, University of Nottingham
Please do come along and talk to us about your requirements
Contact
Marketing Specialist
Milton Road,
Cambridge.
CB4 0FE
Email: smchugh@geneservice.co.uk
29 Oct 2007: Medical Solutions Geneservice Mini Exhibitions
Medical Solutions Geneservice, provider of genomic products and contract research services, will be holding a series of mini exhibitions designed to inform the research community how the Company can help in the areas of:
• DNA Sequencing (free trials available)
• Gene expression analysis
• Genotyping
• Whole Genome Amplification
• cDNA/genomic/miRNA clones and libraries
Planned dates and venues:
v Tuesday 30 October
10am – 2pm
Harwell Medical Research Council
v Wednesday 31 October
10am – 2pm
Cambridge Institute for Medical Research
v Tuesday 6 November
10am – 2pm
Rayne Building, London
v Thursday 8 November
10am – 2pm
Laboratory of Molecular Biology (LMB), Cambridge
v Wednesday 21 November
10am – 2pm
Wellcome Trust Centre for Human Genetics, Oxford
v Thursday 6 December
10am – 2pm
Department of Biochemistry, Bristol University
v Thursday 13 December
10am – 2pm
Royal Veterinary College, Hawkshead
Please do come along and talk to us about your requirements
Contact
Marketing Specialist
Milton Road,
Cambridge.
CB4 0FE
Email: smchugh@geneservice.co.uk
05 Oct 2007: Medical Solutions Extends Partnership with Oxford University and Achieves Extended ISO 9001:2000 Certification
Medical Solutions is pleased to see the expansion of it’s DNA sequencing activities through an extended partnership with the University of Oxford. The DNA sequencing facility previously run by the Department of Pathology has been incorporated into Medical Solutions’ Oxford DNA sequencing laboratory, the second core laboratory to join forces with Medical Solutions since January. The company now has the largest commercial sequencing capability in both Cambridge and Oxford and looks forward to continued growth through similar partnering opportunities.
In addition to this, the sequencing laboratory at Oxford University has received the International Standards Organisation's (ISO) 9001:2000 certification for the provision of functional genomic products and contract research to academic and commercial research communities worldwide and to sequencing/contract research in satellite laboratories in the UK. This follows external validation by Lloyds Register of Quality Assurance (LRQA) a United Kingdom Accreditation Service (UKAS) accredited quality certification body. ISO 9001 is an internationally recognised standard that represents good management practices and aims to ensure that organisations consistently deliver the products or services that meet their clients’ quality requirements. The achievement of ISO 9001:2000 approval reinforces Medical Solutions’ continued commitment to identify and meet the needs and expectations of its customers and achieve, maintain and improve overall operational performance and capabilities
Nick Leaves commented:
"This partnership and certification demonstrates Medical Solutions’ constant determination and commitment to providing elite levels of both product and service quality. We are dedicated to being the premier supplier of genomic products and technical services to our customers."
Contact
20 Aug 2007: Medical Solutions Geneservice chosen to be Applied Biosystems’ UK service provider for SNPlex™ Genotyping System
The Board of Medical Solutions plc (LSE: MLS), the diagnostics and healthcare business, is pleased to announce that its recently acquired genomic services and products business Geneservice Limited has been chosen by Applied Biosystems to be the UK service provider of its SNPlex™ Genotyping System and help broaden access to its genotyping technology. Applied Biosystems is headquartered in Foster City, California, and reported sales of over US$1.9 billion during 2006.
HIGHLIGHTS
- Geneservice to benefit from marketing and technical support;
- Geneservice was selected because of its proven proficiency in executing the SNPlex™ chemistry workflow and
- SNPlex™ platform will enhance Geneservices’ delivery of advanced genotyping services.
As part of Applied Biosystems’ SNPlex™ Service Provider Program, Geneservice will benefit from marketing and technical support - which is expected to enhance its ability to deliver advanced genotyping services to its clients. Geneservice was selected because of its proven proficiency in executing the SNPlex™ chemistry workflow and generating reliable data using GeneMapper™ software for data analysis.
Geneservice will use the Applied Biosystems’ SNPlex™ technology and genotyping and sequencing platforms to offer a system for projects needing to genotype multiple single nucleotide polymorphisms (“SNPs”) from hundreds or thousands of samples.
The SNPlex™ Service Provider Program is intended to enable researchers who do not have access to capillary electrophoresis (“CE”) genetic analysis instrumentation to obtain a flexible and bespoke high-throughput SNP genotyping data solution.
Nick Leaves, Head of Operations for Medical Solutions said: "The SNPlex™ Genotyping System is well suited to the candidate gene association studies that typically follow whole-genome screening. We already have significant expressions of interest in SNPlex™ and have completed over 900,000 custom SNP genotypes in recent months. We are delighted to have had our experience recognised by Applied Biosystems and to have been chosen as its partner for this technology in the UK.”
Contact:
Nick Leaves
Head of Operations
Medical Solutions plc
1 Orchard Place
Nottingham Business Park
Nottingham
NG8 6PX
Tel: +44 (0) 115 973 9012
Fax: +44 (0) 115 973 9013
www.medical-solutions.co.uk
03 Jul 2007: Acquisition by Medical Solutions plc
The Board of Medical Solutions plc (LSE: MLS), the diagnostics and healthcare business specialising in histopathology and cytology services and products, announces that at its Extraordinary General Meeting held today shareholders passed unanimously the resolution for the acquisition of Geneservice Limited.
07 Jun 2007: PROPOSED ACQUISITION OF GENESERVICE LIMITED
The Board of Medical Solutions plc (LSE: MLS), the diagnostics and healthcare business specialising in histopathology and cytology services and products, announces that it has conditionally agreed to acquire the entire issued share capital of Geneservice Limited ('Geneservice') for a total consideration of £3.86 million payable in cash and loan notes.
read more
09 May 2007: Geneservice Wins UK Biotechnology Innovation Award
9th May 2007, Cambridge, UK - Geneservice Ltd, the leading contract research organisation and biological resource supplier, today announced it has won the 2007 East of England Innovation in Enabling Bio-Technology Award. This award recognizes the role research plays in developing technologies that facilitate drug discovery and development. The criteria used were based on innovation in product offering and/or technology, creativity in the business strategy and deal making. Geneservice will now represent the East of England region to compete nationwide in the Department of Trade and Industry’s 2007 UK Bio Entrepreneur of the Year Awards.
Commenting on the significance of this award, Tom Weaver, Geneservice’s CEO said:
“We are extremely pleased to receive this award. Not only is it a great endorsement of our business strategy, but recognizes the amount of success our team has accomplished in only two short years. It is also nice to see that a customer service focused biotech company can be considered for this type of award!”
Contact:
Dr. Cheng-eng Ang
Geneservice Ltd
2 Cambridge Science Park, Milton Road
Cambridge, CB4 0FE
Telephone: +44(0)1223 432600
Fax: +44(0)1223 432601
E-mail: info@geneservice.co.uk
About Geneservice Ltd
Geneservice Ltd was launched in August 2005 following a successful management
buyout of the UK Medical Research Council Biological Resource Centre (MRC
Geneservice). Geneservice offers access to high quality genomic products and
leading contract research for applications in the life sciences, clinical research and
development.
Visit the Geneservice website at www.geneservice.co.uk for more information.
20 Feb 2007: Newcastle University awards large Genotyping project to Geneservice
Cambridge, UK - Geneservice Ltd, the leading contract research organisation and biological resource supplier, today announced that it has been awarded a large genotyping project by The Institute of Human Genetics at Newcastle University on behalf of two National Consortia, for a study into vesicoureteric reflux, a congenital condition which can lead to renal failure. The MRC funded project, to genotype more than 1400 human samples from affected families in the UK and Slovenia was recently subject to an EU tender and Geneservice (GSL) was selected on a range of criteria including: technical specification, price, quality and delivery terms. Financial details of the award were not disclosed.
GSL will initially amplify and quality check the DNA samples using Whole Genome Amplification. Samples will be analysed using high-density Affymetrix GeneChip® Human Mapping arrays to produce genotypes that will then used to perform a whole-genome linkage and association study. The project will begin immediately. The number of samples genotyped in any genome scan is one of the most important factors in determining power. The reduced cost of the Affymetrix high-density arrays coupled with GSL’s ISO 9001:2000 certified processes enables more samples to be run, thereby increasing the power of genetic association studies.
Nick Leaves, Operations Director at GSL said, ‘We’re delighted to have been selected as the best Service Provider for this project. The Affymetrix – GSL partnership on this project will deliver an experimental investigation that could only have been dreamed of just a few years ago. In addition, the cost per genotype is very low because of recent price reductions by Affymetrix. This simply means the customer gets more great data for less money.’
Contact:
Nick Leaves
Operations Director
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge
CB4 0FE
Telephone: +44(0)1223 432600
Fax: +44(0)1223 432601
E-mail: info@geneservice.co.uk
About Geneservice
Geneservice is a worldwide leader in the provision of genomic contract research and the distribution of biological resources for life science research. Since the company’s conception, the genomic services and products have been used throughout the academic, industrial, and government research sectors in fields spanning molecular biology, genomics, proteomics, drug discovery and toxicology. Geneservice headquarters are based in Cambridge, UK, visit www.geneservice.co.uk for more information
NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.
08 Feb 2007: Geneservice acquires the DNA Sequencing facility at Biochemistry Department, University of Oxford
Cambridge, UK - Geneservice Ltd, today announced that it has acquired the sequencing facility at the Biochemistry Department, University of Oxford. The aim is to create an Oxford based one-stop-shop for genomics contract research, including: DNA sample processing, genotyping, mRNA expression analysis, and microbiological clone management. In particular, the Oxford hub will provide customers throughout Oxford and neighboring regions access to more than 10 years of DNA sequencing experience, and the added benefits of online ordering, comprehensive template recovery, direct sample collection and local customer service support.
The existing DNA sequencing facility, within the Biochemistry Department will become Geneservice's local service hub, with existing university personnel transferring to the company and Simon Mayes moving from the Cambridge operations to lead the new team. Simon will be responsible for integrating Cambridge and Oxford activities, particularly the introduction of extensive quality systems and procedures.
Tom Weaver, Geneservice's CEO, commented "Geneservice is really happy to partner with the premier Biochemistry Department in the UK. We plan to grow the hub and its service offerings, particularly as the Department expands into new premises. The ability to work closely within the university environment is helpful since such close adjacencies allows us to provide a better local customer service and form strategic collaborations for introducing new applications and technology platforms. We also see this as the first of several similar alliances around the UK."
On behalf of the dept of Biochemistry, Prof. David Sherratt, Chair of the DNA Sequencing Management Committee, welcomed the new partnership and the extended services that it will bring.
For more information please see www.geneservice.co.uk
Contact:
Simon Mayes or Nick Leaves
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge
CB4 0FE
Telephone: +44(0)1223 432600
Fax: +44(0)1223 432601
E-mail: info@geneservice.co.uk
29 November 2006: Geneservice Ltd announces an agreement to distribute biological
resources developed by Roswell Park Cancer Institute, including
Human and Mouse BAC clones and arrays.
Geneservice Ltd (Cambridge, UK) the leading contract research
organisation and biological resource supplier today announced the
completion of a worldwide license agreement to distribute selected
biological resources developed by world renowned Roswell Park Cancer
Institute (RPCI).
This new license agreement reinforces Geneservice's position as the
leading provider of biological and genomic resources to life science
researchers worldwide. Geneservice is one of the largest cDNA and
genomic clone distribution companies in the world, and its portfolio
of over 12 million clones is constantly growing through license
agreements with leading academic institutions.
The Roswell Park Cancer Institute is a cancer research and treatment
center located in Buffalo, New York. Founded in 1898 by Dr. Roswell
Park, it was the first dedicated medical facility for cancer treatment
and research in the United States. The facility is involved in drug
development and conducts clinical research for cancer treatment.
Commenting on the importance of the agreement, Tom Weaver, CEO stated,
'This agreement increases open access to the international scientific
community to one of the most useful genomic resources ever created.
Some of the libraries now available include those used to sequence the
human and mouse genomes. These are extremely useful for analyzing and
engineering long stretches of DNA for studies in gene regulation,
disease mapping and diagnositcs, imprinting, and chromosome dynamics.
Such libraries are an important addition to our current product
portfolio which also includes important cDNA and RNAi collections"
The Mouse Bac library is available now, for futher information please
click here .
The Human BAC tilepath library will be available early 2007, therefore
please register your interest as soon as possible via the website or
by email to
info@geneservice.co.uk .
Geneservice will be supplying vector, library and individual clones to
both academic and commercial parties. Initially, a kinase-focused subset
will be available, which will be followed by distribution of the
full-sized library. Revenues will be shared by Geneservice, the NKI
and CRT.
Contact
Tom Weaver or Andy Walker
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge CB4 0FE
Phone: +44(0)1223 432600
Fax: +44(0)1223 432601
E-mail:
info@geneservice.co.uk
Notes to Editors:
About Geneservice
Geneservice is a worldwide leader in the provision of genomic
contract research and the distribution of biological resources for
life science research. Since the company's conception, the genomic
services and products have been used throughout the academic,
industrial, and government research sectors in fields spanning
molecular biology, genomics, proteomics, drug discovery and
toxicology. Geneservice headquarters are based in Cambridge, UK,
visit www.geneservice.co.uk for more information.
London, UK; Cambridge, UK; Amsterdam, Netherlands 27 September 2006: Cancer Research Technology Grants Geneservice Ltd. Distribution
Rights of RNA Interference Library Generated at the Netherlands
Cancer Institute
Cancer Research Technology Limited (CRT), the oncology-focused
development and commercialisation company, today announce that they have
granted Geneservice Limited (Geneservice) a worldwide exclusive licence
to distribute the pSUPER RNA interference (RNAi) vector system and
pRETROSUPER vector-based short hairpin RNA (shRNA) library generated by
researchers at the Netherlands Cancer Institute (NKI).
The pSUPER RNAi vector system, developed by Dr Reuven Agami at the
Netherlands Cancer Institute (NKI), enables stable and prolonged
inhibition of target gene expression in mammalian cells. The pRETROSUPER
vector-based library, consisting of almost 24,000 shRNAs complementary
to approximately 8000 genes, was developed by Drs Rene Bernards and
Roderick Beijersbergen and their team, also based at the NKI. With an
emphasis on oncology-related genes, the library includes a high
proportion of candidate drug targets. The library, contains three target
sequences per gene, is sequence validated and is available in single
well format, thereby facilitating high-throughput target validation in
mammalian cells. The pRETROSUPER platform allows introduction of shRNA
expression vectors by transfection and retroviral infection.
Geneservice will be supplying vector, library and individual clones to
both academic and commercial parties. Initially, a kinase-focused subset
will be available, which will be followed by distribution of the
full-sized library. Revenues will be shared by Geneservice, the NKI
and CRT.
Contact
Dr Roisin NicAmhlaoibh
Business Manager
Cancer Research Technology Limited
Phone: +44 207 269 3640
E-mail:
Dr Roisin NicAmhlaoibh
To register your interest in receiving this resource please contact
Dr Sebastien Allouis
Head of Genomic Reagents
Geneservice Ltd
Phone: +44 1223 432609
E-mail:
Dr Sebastien Allouis
Notes to Editors:
About Geneservice
Geneservice Ltd was launched in August 2005 following a successful
management buyout of the UK Medical Research Council Biological
Resource Centre (MRC Geneservice). Geneservice offers access to high
quality genomic products and leading contract research for
applications in the lifesciences, clinical research and development.
Visit the Geneservice website at www.geneservice.co.uk
for more information.
About The Netherlands Cancer Institute
The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
(NKI-AVL) combines a scientific research laboratory with a
specialised clinic. It is the only dedicated cancer center in the
Netherlands. The primary objective of the NKI-AVL is to make a
substantial contribution to combating cancer through a unique
interaction of scientific research and clinical application. For
more information, please visit
www.nki.nl
About Cancer Research Technology
Cancer Research Technology Limited (CRT) is an oncology-focused
development and commercialisation company that realises cancer
patient benefit from publicly- funded research worldwide. CRT works
closely with leading international cancer scientists, their
institutes and funding bodies to protect, develop and commercialise
oncology-related discoveries. CRT is wholly owned by Cancer
Research UK, the largest independent funder of cancer research in
the world. Further information about CRT can be found at
www.cancertechnology.com
1 August 2006: Geneservice Ltd announces an agreement to distribute selected genomic
resources developed by the Wellcome Trust Sanger Institute.
Geneservice Ltd (Cambridge, UK) the leading contract research
organisation and biological resource supplier today announced the
completion of a world wide agreement to distribute selected genomic
resources developed by world renowned Wellcome Trust Sanger Institute.
This agreement further strengthens Geneservice's position as the leading
genomic resource supplier. These Sanger Institute genomic resources are
a significant addition to the reagent portfolio, and will initially add
three important libraries to the existing portfolio of over 12 million
clones.
All genomic resources will be available to order on-line, via the
Geneservice website at http://www.geneservice.co.uk/products/sanger,
customers will receive shipments quickly and efficiently. All orders
will be backed by the usual exceptional level of customer service and
technical support, that customers have come to expect from Geneservice
Ltd.
Commenting on the importance of the agreement, Tom Weaver, CEO stated,
"Geneservice is extremely pleased to be working with Genome Research
to market these unique resources, developed at The Sanger Institute.
Geneservice originated from the UK Medical Research Council when it was
part of Human Genome Program on the Hinxton Genome Campus, so it is
exciting to continue working closely with the Sanger. It is our aim to
provide a portal for scientists from around the world access to one of
the most advanced research programs in the field of genomics. This
agreement further re-enforces our commitment to enabling rapid and open
access to the highest quality biological tools for life science
research."
Contact
Tom Weaver or Andy Walker
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge CB4 0FE
Phone: +44(0)1223 432600
Fax: +44(0)1223 432601
E-mail:
contact
Notes to Editors:
About Geneservice
Geneservice Ltd was launched in August 2005 following a successful
management buyout of the UK Medical Research Council Biological
Resource Centre (MRC Geneservice). Geneservice offers access to
high quality genomic products and leading contract research for
applications in the lifesciences, clinical research and development.
2 June 2006: Geneservice Ltd is selected as one of three preferred suppliers for
DNA sequencing to the Medical Research Council
Geneservice Ltd (Cambridge, UK) the leading contract research provider
today announced they have been selected as one of three preferred
sequencing service providers for the 35 Medical Research Council (MRC)
research sites across the UK.
Geneservice is a privately owned company employing around 30 people with
considerable experience in providing genomic contract research services
to a wide range of customers both in the UK and abroad. Geneservice is
ISO 9001:2000 accredited and offers speedy, high quality data to its
sequencing customers
The company has a dedicated and highly skilled DNA sequencing team who
will provide an efficient and proven service to the MRC scientists.
Roger Turner, Finance and Commercial Director was pleased that
Geneservice had been selected and commented "Geneservice has been
providing several of the MRC sites with high quality DNA sequencing
services for some years, and we are pleased to have been selected as
one of the preferred supplies for the three year contract. We are
committed to providing exceptional customer support and the very best
sequencing data possible using the latest technology"
Contact
Roger Turner or Karen Chandler-Smith
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge CB4 0FE
Phone: +44(0)1223 432600
Fax: +44(0)1223 432601
E-mail
contact
Notes to Editors:
About Geneservice
Geneservice Ltd was launched in August 2005 following a successful
management buyout of the UK Medical Research Council Biological
Resource Centre (MRC Geneservice). Geneservice offers access to
high quality genomic products and leading contract research for
applications in the lifesciences, clinical research and development.
30 May 2006: Geneservice and DNAFORM enter into exclusive distribution agreements - introducing unique worldwide genomic resources
Geneservice Ltd (GSL) of Cambridge England, and Kabushiki Kaisha DNAFORM, of Tokyo Japan, today announced exclusive distribution agreements whereby GSL and DNAFORM will jointly distribute FANTOM™ clones developed by RIKEN as well as other unique genomic resources created by leading international research institutions like the NIH. This strategic alliance will give the international life science community access to the world's largest collection of cDNA and genomic clone resources from key model organisms such as human, mouse, rat, primate, C. elegans, Drosophila, and Xenopus.
"We are excited at the prospect of Geneservice partnering with KK DNAFORM for the ability to combine our clone collections with the impressive resources from RIKEN, and expanding our territorial reach into Asia" said Tom Weaver, CEO for Geneservice.
KK DNAFORM, which is actively working on exploiting the RIKEN cDNA library technology, for which it holds exclusive patents, also welcomed this partnership. "We see this strategic alliance as a way to rapidly increase our product portfolio offered in Japan and other Asian countries, and to effectively market our RIKEN FANTOM™ Clones particularly in the EU" stressed Hirohumi Ujita, KK DNAFORM's CEO.
The new alliance was also welcomed by members of the research community, and recognized as a great step forward to increase the awareness about these clone collections in the public domain, and to make them more easily accessible for researches. Professor Yoshihide Hayashizaki, Project Director of the Genome Exploration Research Group at RIKEN, commented "This partnership is really very important to us, and we are hoping that it will give more researches access to our FANTOM™ Clones. Moreover, it is good to know that for the first time a clone provider in Japan will offer all the clones from the international genome projects." Marc Vidal from the DFCI added "The new paradigm of genomics and systems biology requires the creation of genome-wide clone resources. It is essential that international efforts like this take place to make such valuable resources available to the research community, in particular in Asia where a dedicated clone provider was missing."
Contact
Dr Andrew Walker
Resource Development Manager
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge CB4 0FE Phone: +44(0)1223 432600
Fax: +44(0)1223 432601
E-mail: Dr. Andrew Walker
Notes to Editors:
About Geneservice
GSL is an innovative genomics-based products and contract research company recently formed from the UK Medical Research Council. Their mission is to provide an archiving and distribution portal for emerging genomic reagents, such as bacterial clones and Human DNA samples, generated by academic groups and consortia internationally. GSL also provides access to state-of-the-art high throughput technologies to academic and commercial clients for the study of gene expression and gene mapping, including disease gene identification, DNA sequencing, extraction and whole genome amplification; micro satellite and SNP genotyping; and RNA expression profiling. Geneservice's one-stop service program for genomics researchers is highly regarded for its quality and customer service. For more information please visit www.geneservice.co.uk
About DNAFORM
DNAFORM was established as a RIKEN Venture to commercialise technologies for the analysis of complex transcriptomes developed as part of the RIKEN Mouse Encyclopaedia Project. DNAFORM's technology platform is based on the patented RIKEN Full-Length cDNA Cloning Approach, which offers effective means for Transcriptome Analysis along with resources for target gene cloning. Expanding on this platform, novel approaches can be offered for Transcriptome Annotation based on 5'-Tag sequencing (CAGE), and the identification of genes regulated on the level of Alternative Splicing (ASSETS). In combination with our flexible Library Construction Program, the DNAFORM technology platform can support research and development in Proteomics, Gene Regulation, Gene Discovery, RNAi, or SNP Analysis. For the promotion of science and the easier availability of DNA clones to the research community, DNAFORM developed further together with RIKEN the concept of the DNABook™, which brings together clones of interest and the related information in a printed format easy to handle, store and use. For more information please visit www.dnaform.jp www.geneservice.co.uk
15 May 2006: Geneservice Ltd and RNAx GmbH launch PhenoFiler™ - A unique
service platform for Gene Discovery and Validation
Geneservice Ltd (GSL) Cambridge, UK, the leading contract research
organisation and biological resource centre and RNAx GmbH (RNAx),
Berlin, Germany, a company specialized in RNAi validation technology,
announced today the launch of their new mRNA expression
PhenoFiler™ service platform. This new platform brings
together both companies unique expertise to create a single platform
for gene discovery and validation.
Under the terms of the agreement RNAx provides GSL and its customers
with in vitro si- and shRNA validation technology to complement GSL's
gene expression profiling and network analysis service, and vice versa.
PhenoFiler™ will provide researchers with a complete solution
for comprehensively profiling tens of thousands of genes and then
immediately screening for molecular or cellular phenotypes in a
co-ordinated set of experiments.
RNAx has developed a robust automated platform for
the customized, rapid and cost effective validation of siRNAs, shRNAs
and genetic targets in a broad variety of commonly used cell lines and
primary cells, making the screening, selection and functional validation
of si- and shRNAs affordable, even at high numbers of targets. Through
a number of partnerships with leading European biotech companies, RNAx
makes RNAi technology available to many applications during the target
discovery and validation process - all the way from gene expression
analysis to in vivo validation of more advanced targets.
GSL , a contract research organisation and
biological resource centre, recently formed from the UK Medical
Research Council that brings with it more than 10 years experience as
a national core service laboratory and was one of the first national
service providers of mRNA expression analysis in Europe. GSL has also
developed novel bioinformatics tools for identifying important
relationships between genes, establishing networks based on expression
data.
"This agreement gives benefits to both companies: GSL's customers
through our one-stop approach will have access to gene silencing
technology, and RNAx' customers can take advantage of the full range
of GSL's technologies. The customer will not have the need to look for
additional providers, and will deal with our two companies as if it
was one entity. This will simplify and speed up the service for the
customer. Results will be available faster, because our two companies
know exactly how to integrate our technologies, commented Joerg
Poetzsch, CEO of RNAx.
"We are very pleased to partner with RNAx, as this adds an important
new dimension to our contract research capabilities and customer value",
said Tom Weaver, CEO of Geneservice.
Contact
Geneservice:
Dr Tom Weaver, CEO
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge CB4 0FE
Phone:
+44(0)1223 432602
Fax:
+44(0)1223 432601
E-mail:
Dr. Tom Weaver
RNAx GmbH:
Dr Joerg Poetzsch, CEO
Phone:
+49 30 4863 7389
E-mail:
Dr. Joerg Poetzsch
Notes to Editors:
About Geneservice
Geneservice Ltd was launched in August 2005 from the UK Medical
Research Council and Human Genome Mapping Project, and offers
access to high quality genomic products and leading contract
research for applications in the life sciences, clinical research
and development. For more information visit
www.geneservice.co.uk
About RNAx GmbH
RNAx GmbH is an independent functional genomics research and
service company based on the application of RNA interference.
RNAx's know-how is based on many years of research and development
of reliable high-throughput validation technologies using RNA
interference at the Max Planck Institute for Infection Biology in
Berlin. RNAx offers its customers automated, and thus rapid and
cost effective validation of siRNAs, shRNAs and targets. RNAx was
founded by scientists of the Max Planck Institute for Infection
Biology in Berlin in December 2002, and is financed entirely by
its founders and through the generation of revenues from a number
of renowned companies like Qiagen, Proligo and major international
pharmaceutical companies. www.RNAx.de
05 May 2006: Knockout knockdown library
Geneservice are happy to announce the distribution of our fourth C.
elegans resource in as many months! With over 10 thousand knockdown
targets, some of which are unique to this library, the ORF-RNAi library
is an ideal resource for large scale-screening and individual knockdown
experiments. For more information, please consult the ORF-RNAi website.
20 Apr 2006: Geneservice's commitment to quality is underlined by ISO 9001:2000 certification
Geneservice Ltd (Cambridge, UK) today announced it has received the International Standards Organisation's (ISO) 9001:2000 certification for the provision of functional genomic products and contract research to academic and commercial research communities worldwide. This follows external validation by Lloyds Register of Quality Assurance (LRQA) a UKAS accredited quality certification body. ISO 9001 is an internationally accepted standard that represents good management practices and aims to ensure that organisations consistently deliver the products or services that meet their clients quality requirements.
The achievement of ISO9001:2000 approval reinforces Geneservice's continued commitment to identify and meet the needs and expectations of its customers and achieve, maintain and improve overall operational performance and capabilities.
Tom Weaver, CEO of Geneservice commented
"This certification further demonstrates Geneservice's commitment to the highest levels of product and service quality. The staff's enthusiasm and self motivation was shown clearly by their commitment to the development and application of a Quality Management System at Geneservice"
Contact
Dr Tom Weaver, CEO or Helen Longland, Quality Assurance Manager
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge CB4 0FE
Phone: +44(0)1223 432602
Fax: +44(0)1223 432601
E-mail: info@geneservice.co.uk
Notes to Editors:
About Geneservice
Geneservice Ltd was launched in August 2005 following a successful management buyout of the UK Medical Research Council Biological Resource Centre (MRC Geneservice). Geneservice offers access to high quality genomic products and leading contract research for applications in the lifesciences, clinical research and development. For more information visit www.geneservice.co.uk
March 2006: Wellcome Trust Sanger Institute selects Geneservice Ltd as its key
contract research partner for Whole Genome Amplification
Cambridge, UK Geneservice Ltd, is pleased to announce
that the Wellcome Trust Sanger Institute has chosen Geneservice to
provide whole genome amplification for circa 25,000 samples from
multiple studies including the Wellcome Trust Case Control Consortium
(WTCCC), EPIC (obesity), MalariaGen, and the International 1q type 2
diabetes consortium.
Large sample collections are essential in investigating the molecular
basis of common genetic diseases and susceptibility to pathogens.
Expanding the amount of DNA available will allow multiple future
experiments on these precious samples that have been collected over
many years.
Evaluation of suppliers, was based on a common set of samples tested
post-amplification with the Affymetrix Genechip as well as Illumina
Golden Gate and Infinium technologies. The selection of Geneservice was
based on a combination of responsiveness, performance, quality of
service and value for money.
Tom Weaver, CEO of Geneservice commented
"I am delighted that we have been awarded this
prestigious project against strong international competition. Working
with world class scientific teams and being entrusted to amplify their
samples is a tribute to the dedicated Geneservice team" %lt;/i>
Panos Deloukas of the Wellcome Trust Sanger Institute added
"We looked for a provider to work closely with us to
develop robust protocols for these important projects "
Contact
Dr Tom Weaver, CEO or Roger Turner, Finance and Commercial Director
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge CB4 0FE
Phone:
+44(0)1223 432602
Fax:
+44(0)1223 432601
E-mail:
info@geneservice.co.uk
Notes to Editors:
About Geneservice
Geneservice Ltd was launched in August 2005 following a successful
management buyout of the UK Medical Research Council Biological
Resource Centre (MRC Geneservice). Geneservice offers access to
high quality genomic products and leading contract research for
applications in the lifesciences, clinical research and development.
For more information visit
www.geneservice.co.uk
About Whole Genome Amplification
Whole Genome Amplification is an amplification method using
degenerate oligos to produce large amounts of genomic DNA from small
amounts of starting material. For more information on Whole Genome
Amplification visit http://www.geneservice.co.uk/services/samples/WGA_service.jsp
About Wellcome Trust Sanger Institute
The Sanger Institute is a genome research institute primarily
funded by the Wellcome Trust. Our purpose is to further the
knowledge of genomes, particularly through large scale sequencing
and analysis.
27 February 2006: Geneservice Ltd forms strategic alliance with VWR
New specialist service division at VWR to provide customer-facing
support for Geneservice, the leading genomic contract research
organization.
Cambridge, UK Geneservice Ltd, today announced a
five-year strategic alliance with VWR for sales representation of the
company's leading contract research platforms. Customers in Europe, USA
and the UK will now be able to access industry leading genotyping, gene
expression and DNA handling capabilities at Geneservice via their local
VWR specialist service representative. VWR's sales and marketing
operation currently serves over 250,000 customers with an extensive
worldwide specialist sales network.
This strategically important agreement, the first since the management
buyout of MRC Geneservice in 2005, is further evidence of Geneservice's
commitment to providing the very latest discovery contract research
platforms to a growing customer base.
Tom Weaver, CEO at Geneservice commented
"Our new alliance with VWR is strategically important
for us. It significantly increases our geographical coverage and makes
our leading contract research platforms available to more researchers
worldwide. We are delighted to have been selected by VWR to be one
of the first companies to be included in the VWR BioSciences
programme."
The alliance offers an excellent balance and fit between Geneservice's
established expertise in genomic contract research and VWR's marketing
capabilities, global market strength and representation. Geneservice
customers will benefit from the proximity with their local VWR
specialist service representative, and will have direct access to
leading technology and a team of dedicated, highly qualified scientists
with extensive project management experience at Geneservice. With over
10 years experience as a national genomics core laboratory and
bioinformatics infrastructure, Geneservice has both the capacity and
ambition to move beyond the UK market. Working with VWR will
substantially increase Geneservice's exposure by promoting its expert
contract research program and customer service to academic, clinical,
government, biotech and pharma labs world-wide.
Dr. Weaver also highlighted that
"Working with VWR in setting up this alliance has been
terrific, and it has been more like partnering with another small
start-up company instead of what is in reality a very large corporation.
This has facilitated our ability to move quickly and effectively, and I
believe this says a lot about VWR BioSciences innovative management team.
Even though selling services will be a new challenge for VWR reps, so
far there has been excellent communication with our scientists and
shared vision on how to make this venture a success and swiftly grow
the business."
VWR International is a global distributor providing a diversified
range of products and has recently established VWR Biosciences to
provide specialist services, such as those provided by Geneservice,
to the bioscience and lifescience Industries. VWR's primary customers
work in the pharmaceutical, life science, chemical, technology, food
processing and consumer product industry throughout North America and
Europe.
Zishan Haroon, General Manager and Global VP of VWR BioSciences
commented
"The BioSciences programme extends above and beyond
VWR's traditional role by providing research services for our
customers' drug discovery and development needs. Establishing a
partnership with Geneservice helps accomplish exactly this, offering
an industry leader in DNA expression and microarray services to our
customers. Geneservice is a highly reputable firm, delivering the
highest quality services with the utmost efficiency. Our commitment
to excellence ensures that the researcher can have the highest
confidence in the value Geneservice provides."
Contact
Dr Tom Weaver, CEO
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge CB4 0FE
Phone:
+44(0)1223 432600
Fax:
+44(0)1223 432601
E-mail:
info@geneservice.co.uk
Notes to Editors:
About Geneservice
Geneservice Ltd was launched in August 2005 following a successful
management buyout of the UK Medical Research Council Biological
Resource Centre (MRC Geneservice). Geneservice offers access to
high quality genomic products and leading contract research for
applications in the lifesciences, clinical research and development. For more information visit
www.geneservice.co.uk
February 2006: FANTOM™ 3 Launch
After the success of the Mouse DNABook™, Geneservice are happy to
announce the distribution of the more than 100 thousand FANTOM™ 3
clones. The clones are full-length sequenced, with comprehensive
supporting annotation and databases.
Single clones or the complete library are ready for distribution! For
more information, please go to our FANTOM™ 3 webpage.
February 2006: Geneservice Announce the Appointment of Dr Andy Richards as
Non-Executive Chairman.
Geneservice Ltd (Cambridge, UK), announced today
that the Board of Directors has appointed Dr Andy Richards as
non-executive Chairman. Dr Richards is a well known Biotechnology
entrepreneur having been a founder of several successful Cambridge
biotechnology companies including Chiroscience, Arakis, Cambridge
Biotechnology and Daniolabs. He holds a number of non-executive
director positions including Vectura group plc, Daniolabs, Biowisdom,
Babraham Bioscience Technology and Cancer Research Technology (the
commercial arm of CR-UK). He is a director of the UK Bioindustry
Association and this year was voted both Cambridge Evening News
Businessman of the Year as well as one of the Top100 Living
Contributors to Biotechnology.
This new appointment follows on from the successful management buyout
of Geneservice from the UK MRC in August 2005. On his appointment to
the board of Geneservice Dr Richards said,
" Geneservice have already demonstrated that they have
real potential to develop into a major provider of specialist high
quality contract research and reagents to the life sciences and
rapidly growing biotechnology industry. The strong and committed team
that led the management buyout have ambitious plans to grow Geneservice
and I am delighted to have the opportunity to help them achieve
this."
CEO of Geneservice Dr Tom Weaver added,
"We are a young company and our aim was to bring in
someone with extensive knowledge of biotechnology and experience with
small startup companies. Andy's expertise and networking ability is
exactly what we need at this stage of our development, plus he shares
our vision to rapidly build up our product and service portfolio. His
infectious passion for innovation and getting the most out of our
people, operations and business opportunities will add so much to our
senior management team."
Notes to Editors:
About Geneservice
Geneservice Limited was launched in August 2005 following a
successful management buyout of the UK Medical Research Council
Biological Resource Centre (MRC geneservice). GSL offers genomic
products and expert contract research for applications in the life
sciences and clinical research and development. It provides access
to high quality, leading edge genomic products essential for
manipulating gene and protein function in the majority of model
organisms, including Mouse and Man. GSL also carries out expert
technology support on a contract basis. The management team comes
with a proven track record at running a National Biological
Resource Centre and a super-core laboratory, guaranteeing excellent
customer service and access to a "one-stop-shop" for many genomic
applications. Our market has international reach with over 900
institutional customers from a database of 21,000 registered users
from over 40 countries, and includes: Universities, Charities,
Government labs, Biotech and Pharmaceutical companies. These
attributes place GSL in a powerful and unique position to fully
utilize the commercial potential of emerging genomic research in
academia and translate these discoveries into validated, high
quality, products and contract research. For more information about
Geneservice Limited, its products and research support program log
on to the website at www.geneservice.co.uk
.
February 2006: "Sequencing Teams Unite"
Geneservice Ltd and the University of Cambridge Department of Genetics
are pleased to announce that from the 1st February 2006 the will be
some exciting changes to the availability of contract sequencing within
the city. The two sequencing teams are joining forces to give customers
an improved sequencing and genotyping service at a lower price.
The price for sequencing within the University will drop by 30%.
Everything else stays the same: the same personnel, the same
instrumentation and the same chemistry in summary; the same high
quality service but for less money! The collaboration promises that
turnaround times will be unchanged or improved. Clinics will be held
weekly in the department of Genetics to allow customers to discuss any
sequencing issues in person. In addition, there will be new services
coming on stream as a result of this venture, including: Geneservice's
template recovery process, online ordering system and improved options
for sequencing difficult templates.
Chris Maddren, the department of Genetics Sequencing facility manager
said:
"We are committed to maintaining the highest quality
results in the shortest possible time and I am looking forward to
working at Geneservice "
Nick Leaves, Operations Director at Geneservice said:
"This is a fantastic example of the type of
collaboration we want to do. Chris has made an enormous success of the
Genetics Sequencing facility and was an obvious partner for us in
expanding the Geneservice Sequencing provision in Cambridge.
"
Contact
Chris Maddren or Nick Leaves
Geneservice Ltd
2 Cambridge Science Park
Milton Road
Cambridge CB4 0FE
Phone:
+44(0)1223 432600
Fax:
+44(0)1223 432601
E-mail:
sequencing@geneservice.co.uk
December 2005: "C. elegans Promoter Library"
A set comprising of more than six thousand C. elegans
promoters have been launched! The library format is in 71-microtitre
plates, 96-well format. Single clones, full-set or re-arrayed subsets
are available from us.
For further information, please go to C. elegans
Promoterome Library
November 2005: "Compliment your work with a C. elegans
Fosmid Library"
We are happy to announce the launch a comprehensive C. elegans Fosmid
library. The N2 based library is the first of it's kind to be
distributed, and will be and excellent accompaniment to our every
increasing portfolio of resources.
For more information please
go to C.
elegans Fosmid Library
" C. elegans re-arrays"
Owing to the great success of Julie Ahringer's C. elegans
RNAi feeding library, Geneservice Ltd are launching 3 subsets
of the library. The sub-sets knockdown genes associated with Chromatin,
Phosphatase and Transcription factors.
For more information please go to C. elegans RNAi .
September 2005: "Amplify your results with WGA aliquots"
Whole Genome Amplified (WGA) DNA aliquots have been prepared from a
diverse range of organisms, to the highest of qualities. Downstream
applications may include: PCR, library construction, southern blotting
and SNP analysis. If you would like further information please visit
our WGA aliquot
information page
September 2005: Launch of Mouse Genome Encyclopaedia
In AD 105, the Chinese court official, Ts´ai Lun, invented
papermaking. Since then, this ubiquitous material has continued to
play an influential role in many of our civilizations. As we embark
into the new Millennium however, we are dominated by the progress
that has been made in computer science, thus triggering a complete
change in our commercial and private communication behaviour.
Does this mean that the paper era will come to an end? The answer is
most definitely "No". This new resource is one of the many
reasons why.
Geneservice Ltd is happy to announce the distribution of the Mouse
Encyclopaedia DNABook™. The book comprises of 60,770
full-length
mouse cDNA clones spotted onto paper and bound in an A5 size book.
The book is supported by databases for searching individual clones by
either location in the book, or gene ID. Furthermore, many functional
annotations may also be accessed.
For more information please visit: Mouse Genome Encyclopaedia
.
06 June 2005: MRC annouces the buyout of MRC Geneservice
The MRC has given formal approval to a Management Buyout by the
management team of MRC geneservice. The new company will be known as
Geneservice Limited (Geneservice). MRC geneservice has successfully
run as a Resource Centre and Contract Research Organisation within
the MRC since October 2001, providing an ever-increasing range of
important genomic resources and services to an international customer
base. These products and services will continue to be available through
Geneservice and new offerings that add value to our customer's research
are being actively sourced.
For full press release
click here
January 2005: "Opening Research Frontiers using a C. jejuni ORF
library."
The team at MRC geneservice are delighted to announce the distribution
of a Camylobacter jejuni Open Reading Frame (ORF)
library. The proteome-scale expression clone set comprises of more than
1,600 ORF's. Jodi Parrish, Russell Finley's laboratory Wayne State
University School of Medicine, constructed the library by utilizing the
endogenous recombination system of E.coli. MRC
geneservice offers the complete clone set of 17 plates 96-well
microtitre plates or individual clones, for research purposes only.
After expression, affinity purification can be performed on the proteins
using either GST or His-tags. There are many post-genomic applications
that can be carried out using the library.
More information on the
C. jejuni ORF resource
June 2004: TURNING MOLEHILLS INTO MOUNTAINS
MRC geneservice launches new Whole Genome Amplification service
Cambridge, UK - Genome researchers struggling with
minute quantities of DNA and degraded samples can breathe a sigh of
relief with the launch of MRC geneservice's (MRCg) Whole Genome
Amplification service. The new service bolsters MRCg's range of genomic
services that include DNA sequencing, SNP genotyping, microsatellites
and RNA expression analysis.
With the addition of Whole Genome Amplification (WGA), MRCg will be able
to amplify small quantities of precious DNA to provide sufficient
quantities for larger scale and multiple projects. MRCg's one-stop
service for genomic researchers is setting the standards for quality,
turnaround time and price, and WGA customers will also benefit from
discounts on subsequent genotyping.
In order to offer the best possible service to genotyping and sample
banking clients, MRCg undertook its own comparison of different WGA
methods. The result has been an agreement with Molecular Staging Inc
(MSI) for MRCg to provide a Whole Genome Amplification service using
MSI's proprietary REPLI-g&trade technology. 'Technically the MSI
system proved superior on our samples to the other systems tested and
provides a very effective QC for the end product. This prevents the
researcher wasting valuable time and money on genotyping highly degraded
samples' said Dr Cheng-Eng Ang, MRC DNA Bank Network Manager, who will
be managing the service.
'Partially degraded samples and irreplaceable small quantities of DNA
are two of the most common causes of failure in genotyping projects'
said Roger Turner, MRCg's CBO. 'Whilst no method can guarantee to rescue
highly degraded DNA, MSI's system provides assurance on quality before
embarking on further work and provides sufficient quantities for
multiple future experiments.'
'The whole genome amplification technology is truly cutting edge and
will have a substantial impact on many applications, such as genetic
mapping, pathogen identification, forensics and embryonic disease
diagnosis. That is why a key milestone for our DNA banking program has
been the introduction of effective whole genome amplification for the
long term archiving of clinical samples and genotyping. By partnering
with MSI we are able to meet our in-house R&D objective and also
provide a beneficial contract service open to the research community.'
said Tom Weaver, MRC geneservice's CEO.
'We are delighted that MRC geneservice chose our proprietary whole
genome amplification technology as the basis for their service offering,'
said Dr. Richard Barker, Chairman and CEO of Molecular Staging Inc. 'MRC
geneservice joins a long list of prestigious institutes worldwide that
have evaluated and chosen MSI's REPLI-g&trade technology on the basis of
performance. Our partnership with MRC geneservice enables us to expand
our ability to provide REPLI-g&trade whole genome amplification to
an ever growing number of global scientists.'
www.geneservice.co.uk
For more information, please visit WGA service
Notes to Editors:
MRC geneservice
1. MRC geneservice is a division of the Medical Research Council's
Rosalind Franklin Centre for Genomics Research and encourages
the use of leading edge technology in genomic research. For
more information about MRC geneservice, its products and services
log on to the website at www.geneservice.co.uk
2. The Medical Research Council (MRC) is a national organisation
funded by the UK tax-payer. Its business is medical research
aimed at improving human health. The research it supports
and the scientists it trains meet the needs of the health
services, the pharmaceutical and other health-related industries
and the academic world. MRC has funded work that has led to
some of the most significant discoveries and achievements
in medicine in the UK. About half of the MRC's expenditure
of over £413 million is invested in its 40 Institutes,
Units and Centres, where it employs its own research staff.
The remaining half goes in the form of grant support and training
awards to individuals and teams in universities and medical
schools. Web site at: http://www.mrc.ac.uk
Molecular Staging Inc.
Molecular Staging Inc. (MSI) has developed a range of
transformational products and services based on its advanced
amplification technologies. These products and services include
REPLI-g&trade whole genome amplification kits and services, a
rapid, reliable method of generating unlimited DNA from a few cells
to address DNA constraints arising from the rapid growth in the
number and variety of genetic tests. MSI has also developed an
integrated proteomics chip based discovery service, which offers a
powerful new way to identify individual and multiplexed sets of
biomarkers to enable new, more effective drugs and diagnostics.
http://www.molecularstaging.com
January 2004: SILENCE OF THE GENES
MRC geneservice launches comprehensive Drosophila
RNAi library.
Cambridge, UK - MRC geneservice has announced the launch
of their extensive new Drosophila RNA interference
(RNAi) library. Encompassing over 90% of the Drosophila
genome, researchers can study the function of specific genes
through genome-wide screens - a first step in shedding new
light on disease processes and possible drug targets.
To read full press release please click
here (Adobe PDF format 244K).
To order the Drosophila RNAi please click here
January 2004: Available January 2004
If interested in ordering, we advise that you can register
and sign the MTA in advance
Drosophila genome RNAi library
A set of 13,600 RNAi constructs are available from MRC geneservice
which covers 90% of
January 2004: Available January 2004
If interested in ordering, we advise that you can register
and sign the MTA in advance
Drosophila genome RNAi library
Available NOW - 24th November 2003
Subsets of the I.M.A.G.E. Consortium resources
The Mouse Pancreas Genes subset [IRBD, IRBE]
This set of 7000 mouse genes has been rearrayed by the K.
Kaestner laboratory (University of Pennsylvania) in 96-well
format. Each plate contains clones from one vector only. There
are 4 partially-full plates.
This resource is available as a plate set, or as Individual clones.
G PROTEIN COUPLED RECEPTORS (GPCR) Clone set [IRBI.IRBF]
Guthrie cDNA Resource Centre (
http://www.guthrie.org/AboutGuthrie/Research/CDNA/ ),
a non-profit organization, provides full-length cDNA clones
encoding human signal transduction proteins to the research
community. Available as plates or individual clones.
For more details please
click here .
20 November 2003: Dear Researcher
MRC geneservice announces new benefits for its
Affymetrix clients
Improved service - lower prices!
MRCg is pleased to announce that it is the first UK service
provider to own the GeneChip Scanner 3000 enabled for High
Resolution Scanning.
This allows us to make our Affymetrix GeneChip service available
to you on Affymetrix latest high-density chips ONLY READABLE
WITH THE NEW SCANNER. We are therefore able to make significantly
more data available to you at our lowest ever prices.
Our price scales have been lowered and simplified, with price
breaks for larger experiments. All prices can be seen here.
here.
For orders placed and samples received by 31 January 2004
we will offer a further 10% DISCOUNT on these prices.
We will also agree with you a GUARANTEED DELIVERY DATE for
your results. If you deliver samples by the agreed time and
we fail to deliver your results by the agreed date you will
receive a further 10% DISCOUNT!
Examples of the NEW services we are able to offer are:
Data sheets on the above products can be found at
http://www.affymetrix.com/products/arrays/index.affx
To discuss your requirements further and place your order
please contact us by e-mail
microarrays@geneservice.co.uk quoting reference AFFY03.
We look forward to hearing from you.
Yours Sincerely
Roger J L Turner
BSc FCA
Finance & Commercial Director
|
